PURPOSE: BRCA2 rearrangements are rare genetic events. A large BRCA2 genomic insertion was recurrently observed in our participants, and we sought to characterize it at the molecular and phenotypic level. PATIENTS AND METHODS: We studied 210 high-risk breast/ovarian cancer families. Fifty-three probands were fully screened for BRCA1/2 mutations, and three of 53 had a large insertion in exon 3 of BRCA2. This finding was analyzed by polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), and sequencing. An additional 157 consecutive families were screened for this mutation by a three-step PCR method. Phenotype and haplotype analysis was also performed. RESULTS: Sixteen BRCA mutations were observed in 19 of 53 patients (36% detection rate). A recurrent Alu motif insertion in position c.156_157 was observed after sequencing of an abnormal fragment obtained after the amplification of BRCA2 exon 3. RT-PCR revealed exon 3 skipping. Screening of this rearrangement identified 14 additional families (out of 157). In total, 17 (8%) of 210 high-risk families ascertained in our clinic were positive for this mutation. Segregation of a common haplotype (from D13S260 to D13S1695) confirmed a common origin, estimated to have occurred 2,400 to 2,600 years ago. The following four cancer phenotypes were observed in the 17 positive families: female breast (n = 9), male breast (n = 4), breast/ovarian (n = 2), and heterogeneous (n = 2). Male breast cancer was more frequently observed in c.156_157insAlu-positive families compared with negative families (23% v 12%, respectively), and 33% of all male breast cancer families with an identified BRCA mutation were c.156_157insAlu positive. CONCLUSION: c.156_157insAlu is a founder mutation of Portuguese origin and is the most frequent BRCA2 rearrangement described to date.
PURPOSE:BRCA2 rearrangements are rare genetic events. A large BRCA2 genomic insertion was recurrently observed in our participants, and we sought to characterize it at the molecular and phenotypic level. PATIENTS AND METHODS: We studied 210 high-risk breast/ovarian cancer families. Fifty-three probands were fully screened for BRCA1/2 mutations, and three of 53 had a large insertion in exon 3 of BRCA2. This finding was analyzed by polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), and sequencing. An additional 157 consecutive families were screened for this mutation by a three-step PCR method. Phenotype and haplotype analysis was also performed. RESULTS: Sixteen BRCA mutations were observed in 19 of 53 patients (36% detection rate). A recurrent Alu motif insertion in position c.156_157 was observed after sequencing of an abnormal fragment obtained after the amplification of BRCA2 exon 3. RT-PCR revealed exon 3 skipping. Screening of this rearrangement identified 14 additional families (out of 157). In total, 17 (8%) of 210 high-risk families ascertained in our clinic were positive for this mutation. Segregation of a common haplotype (from D13S260 to D13S1695) confirmed a common origin, estimated to have occurred 2,400 to 2,600 years ago. The following four cancer phenotypes were observed in the 17 positive families: female breast (n = 9), male breast (n = 4), breast/ovarian (n = 2), and heterogeneous (n = 2). Male breast cancer was more frequently observed in c.156_157insAlu-positive families compared with negative families (23% v 12%, respectively), and 33% of all male breast cancer families with an identified BRCA mutation were c.156_157insAlu positive. CONCLUSION:c.156_157insAlu is a founder mutation of Portuguese origin and is the most frequent BRCA2 rearrangement described to date.
Authors: Ja Young Cho; Dae-Yeon Cho; Sei Hyun Ahn; Su-Youn Choi; Inkyung Shin; Hyun Gyu Park; Jong Won Lee; Hee Jeong Kim; Jong Han Yu; Beom Seok Ko; Bo Kyung Ku; Byung Ho Son Journal: Fam Cancer Date: 2014-06 Impact factor: 2.375
Authors: Paul A van der Zwaag; Ingrid A W van Rijsingen; Angeliki Asimaki; Jan D H Jongbloed; Dirk J van Veldhuisen; Ans C P Wiesfeld; Moniek G P J Cox; Laura T van Lochem; Rudolf A de Boer; Robert M W Hofstra; Imke Christiaans; Karin Y van Spaendonck-Zwarts; Ronald H Lekanne dit Deprez; Daniel P Judge; Hugh Calkins; Albert J H Suurmeijer; Richard N W Hauer; Jeffrey E Saffitz; Arthur A M Wilde; Maarten P van den Berg; J Peter van Tintelen Journal: Eur J Heart Fail Date: 2012-07-20 Impact factor: 15.534
Authors: Adana A M Llanos; Wayne A Warner; Silvana Luciani; Tammy Y Lee; Smriti Bajracharya; Simeon Slovacek; Veronica Roach; Marjorie Lamont-Greene Journal: Cancer Causes Control Date: 2017-09-15 Impact factor: 2.506
Authors: Miguel A M Moreira; Irina G Bobrovnitchaia; Maria Angélica F D Lima; Anna Cláudia E Santos; Jesus P Ramos; Kelly R L Souza; Ana Peixoto; Manuel R Teixeira; Fernando R Vargas Journal: Fam Cancer Date: 2012-12 Impact factor: 2.375
Authors: Sofia Maia; Marta Cardoso; Paula Paulo; Manuela Pinheiro; Pedro Pinto; Catarina Santos; Carla Pinto; Ana Peixoto; Rui Henrique; Manuel R Teixeira Journal: Fam Cancer Date: 2016-01 Impact factor: 2.375